LLY

1,089.02

+1.04%↑

JNJ

232.35

+0.99%↑

ABBV

215.32

+0.69%↑

UNH

383.51

+1.25%↑

MRK

121.71

+0.85%↑

LLY

1,089.02

+1.04%↑

JNJ

232.35

+0.99%↑

ABBV

215.32

+0.69%↑

UNH

383.51

+1.25%↑

MRK

121.71

+0.85%↑

LLY

1,089.02

+1.04%↑

JNJ

232.35

+0.99%↑

ABBV

215.32

+0.69%↑

UNH

383.51

+1.25%↑

MRK

121.71

+0.85%↑

LLY

1,089.02

+1.04%↑

JNJ

232.35

+0.99%↑

ABBV

215.32

+0.69%↑

UNH

383.51

+1.25%↑

MRK

121.71

+0.85%↑

LLY

1,089.02

+1.04%↑

JNJ

232.35

+0.99%↑

ABBV

215.32

+0.69%↑

UNH

383.51

+1.25%↑

MRK

121.71

+0.85%↑

Home・Akciju saraksts・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Atvērts

13.17 1.31

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

12.72

Max

13.59

Galvenie mērījumi
By Trading Economics
Ienākumi	-1.4M -14M
EPS	-0.15
Darbinieki	37
EBITDA	-2.7M -15M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+150.59% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 6. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-241M 1.1B
Iepriekšējā atvēršanas cena	11.86
Iepriekšējā slēgšanas cena	13.17

Corvus Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 26. maijs 16:52 UTC

Galvenie ziņu notikumi

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

2026. g. 26. maijs 23:57 UTC

Peļņas

Sociedad Quimica 1Q Rev $1.76B >SQM

2026. g. 26. maijs 23:57 UTC

Peļņas

Sociedad Quimica 1Q EPS $1.28 >SQM

2026. g. 26. maijs 23:48 UTC

Tirgus saruna

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

2026. g. 26. maijs 21:54 UTC

Peļņas

Webco Industries 3Q EPS $11.61 >WEBC

2026. g. 26. maijs 21:54 UTC

Peļņas

Webco Industries 3Q Sales $179.6M >WEBC

2026. g. 26. maijs 21:48 UTC

Tirgus saruna

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

2026. g. 26. maijs 21:00 UTC

Tirgus saruna

ESG Roundup: Market Talk

2026. g. 26. maijs 20:58 UTC

Iegādes, apvienošanās, pārņemšana

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

2026. g. 26. maijs 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 26. maijs 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 26. maijs 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 26. maijs 19:22 UTC

Tirgus saruna

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

2026. g. 26. maijs 19:17 UTC

Tirgus saruna

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

2026. g. 26. maijs 18:56 UTC

Tirgus saruna

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

2026. g. 26. maijs 18:03 UTC

Tirgus saruna

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

2026. g. 26. maijs 17:42 UTC

Tirgus saruna

Grains Await Fresh Trading Catalyst -- Market Talk

2026. g. 26. maijs 17:33 UTC

Tirgus saruna

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

2026. g. 26. maijs 17:21 UTC

Tirgus saruna

Canada Faces a Labor Market Squeeze -- Market Talk

2026. g. 26. maijs 16:52 UTC

Tirgus saruna

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

2026. g. 26. maijs 16:43 UTC

Tirgus saruna

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

2026. g. 26. maijs 16:24 UTC

Tirgus saruna

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

2026. g. 26. maijs 16:21 UTC

Tirgus saruna

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

2026. g. 26. maijs 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 26. maijs 16:20 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2026. g. 26. maijs 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 26. maijs 16:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Auto & Transport Roundup: Market Talk

2026. g. 26. maijs 16:16 UTC

Tirgus saruna

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

2026. g. 26. maijs 16:01 UTC

Tirgus saruna

Bitcoin Lower as Stress Builds for Holders -- Market Talk

2026. g. 26. maijs 15:21 UTC

Tirgus saruna

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Salīdzinājums

Cenas izmaiņa

Corvus Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

150.59% augšup

Prognoze 12 mēnešiem

Vidējais 31.6 USD 150.59%

Augstākais 40 USD

Zemākais 27 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Corvus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

5 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 5 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Corvus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.